Holen Sie sich die Stockscreener-App
32.30
0.69%
0.22
Handel nachbörslich:
32.30
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CYTK?
Forum
Prognose
Aktiensplit
Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten
Shareholders That Lost Money on Cytokinetics, Incorporated(CYTK) Should Contact Levi & Korsinsky about Securities Fraud InvestigationCYTK - ACCESS Newswire
Insider Sell Alert: Kaye Edward M. MD Sells Shares of Cytokineti - GuruFocus
Cytokinetics (CYTK) Down 1.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Cytokinetics at Jefferies Conference: Aficamten’s Market Expansion - Investing.com India
Insider Sell Alert: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cetera Investment Advisers Decreases Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
Cytokinetics, Incorporated (NASDAQ:CYTK) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Cytokinetics (NASDAQ:CYTK) Given New $84.00 Price Target at Mizuho - Defense World
Cytokinetics (CYTK) Stock Update: Mizuho Lowers Price Target | C - GuruFocus
Cytokinetics (CYTK) Gets Price Target Reduction from Mizuho Anal - GuruFocus
Cytokinetics to Participate in the Jefferies Global Healthcare Conference - The Manila Times
Cytokinetics (CYTK) Stock Update: Mizuho Lowers Price Target | CYTK Stock News - GuruFocus
Mizuho Cuts Price Target on Cytokinetics to $84 From $103, Keeps Outperform Rating - marketscreener.com
Cytokinetics’ SWOT analysis: aficamten’s potential reshapes HCM treatment landscape - Investing.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Investors to Connect - ACCESS Newswire
Cytokinetics at RBC Conference: Strategic Insights on Drug Development By Investing.com - Investing.com Canada
Protect Your Investment: Contact Levi & Korsinsky About the Cytokinetics, Incorporated (CYTK) Investigation - ACCESS Newswire
BNP Paribas Financial Markets Trims Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
Spinal Muscular Atrophy Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme - Barchart.com
Cytokinetics (CYTK) Showcases Promising Aficamten Data for HCM T - GuruFocus
Cytokinetics (CYTK) Showcases Promising Aficamten Data for HCM Treatment | CYTK Stock News - GuruFocus
Cytokinetics Presents Additional Data Related to Aficamten at th - GuruFocus
Cytokinetics Announces SEQUOIA-HCM Analysis Results Highlighting Aficamten's Efficacy and Disparities in Hypertrophic Cardiomyopathy Outcomes Across Patient Demographics - Nasdaq
Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress - The Manila Times
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Ru - GuruFocus
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - TradingView
Revenue Downgrade: Here's What Analysts Forecast For Cytokinetics, Incorporated (NASDAQ:CYTK) - Yahoo Finance
Cytokinetics (NASDAQ:CYTK) Upgraded at Cantor Fitzgerald - Defense World
Cytokinetics Grants $1.2M in Equity Awards: New Hires Signal Growth in Cardiovascular Drug Development - Stock Titan
Cytokinetics (NASDAQ:CYTK) Earns Buy Rating from Needham & Company LLC - Defense World
Insider Sell: Muna Bhanji Sells 1,454 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics to Host Symposium on Contemporary Landscapes in Mus - GuruFocus
Cytokinetics (CYTK) to Host Muscle Biology Symposium in 2025 | C - GuruFocus
Cytokinetics (CYTK) to Host Muscle Biology Symposium in 2025 | CYTK Stock News - GuruFocus
Exclusive Muscle Biology Summit: Genentech, Stanford, and Penn Leaders Join Cytokinetics Research Symposium - Stock Titan
Bluebird extends deal deadline; Affimed files for insolvency - BioPharma Dive
Needham Reiterates Buy Rating on Cytokinetics (CYTK) with $72 Price Target | CYTK Stock News - GuruFocus
Cytokinetics builds its best-in-class case for aficamten - biocentury.com
Cytokinetics (CYTK) Rallies as Phase 3 Trial Succeeds for Lead D - GuruFocus
Stifel maintains confidence in Cytokinetics stock post-trial success By Investing.com - Investing.com Canada
Cytokinetics Unusual Options Activity - Nasdaq
Cytokinetics gets an ‘incremental’ win for delayed heart drug - Endpoints News
Cytokinetics stock rises on Phase 3 trial win (CYTK:NASDAQ) - Seeking Alpha
Cytokinetics (CYTK) Reports Positive Results from Phase 3 Clinical Trial | CYTK Stock News - GuruFocus
Cytokinetics Reports Positive Results From Phase 3 MAPLE-HCM Study - Nasdaq
Cytokinetics Announces Positive Topline Results From MAPLE-HCM | - GuruFocus
Cytokinetics Announces Positive Topline Results From MAPLE-HCM | CYTK Stock News - GuruFocus
Cytokinetics Announces Positive Topline Results From MAPLE-HCM - The Manila Times
Aficamten outperforms beta blocker in HCM trial - Investing.com
Aficamten outperforms beta blocker in HCM trial By Investing.com - Investing.com India
Cytokinetics' heart disease drug meets main goal in late-stage study - marketscreener.com
Dimensional Fund Advisors LP Trims Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
Cytokinetics, Incorporated Being Investigated on Behalf of Cytokinetics, Incorporated Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire
0.00%
2.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):